Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

L-arginine in combination with sildenafil potentiates the attenuation of hypoxic pulmonary hypertension in rats

H. Al-Hiti, M. Chovanec, V. Melenovský, O. Vajnerová, A. Baňasová, J. Kautzner, J. Herget

. 2013 ; 62 (6) : 589-595.

Jazyk angličtina Země Česko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14069004

Grantová podpora
NT13358 MZ0 CEP - Centrální evidence projektů

Chronic hypoxia induces an increased production of nitric oxide (NO) in pulmonary prealveolar arterioles. Bioavailability of the NO in the pulmonary vessels correlates with concentration of L-arginine as well as activity of phosphodiesterase-5 enzyme (PDE-5). We tested a hypothesis whether a combination of L-arginine and PDE-5 inhibitor sildenafil has an additive effect in reduction of the hypoxic pulmonary hypertension (HPH) in rats. Animals were exposed to chronic normobaric hypoxia for 3 weeks. In the AH group, rats were administered L-arginine during chronic hypoxic exposure. In the SH group, rats were administered sildenafil during chronic hypoxic exposure. In the SAH group, rats were treated by the combination of L-arginine as well as sildenafil during exposure to chronic hypoxia. Mean PAP, structural remodeling of peripheral pulmonary arterioles (%DL) and RV/LV+S ratio was significantly decreased in the SAH group compared to hypoxic controls even decreased compared to the AH and the SH groups in first two measured parameters. Plasmatic concentration of cGMP and NOx were significantly lower in the SAH group compared to hypoxic controls. We demonstrate that NO synthase substrate L-arginine and phosphodiesterase-5 inhibitor sildenafil administered in combination are more potent in attenuation of the HPH compared to a treatment by substances given alone.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14069004
003      
CZ-PrNML
005      
20190920124849.0
007      
ta
008      
140825s2013 xr d f 000 0|eng||
009      
AR
024    7_
$a 10.33549/physiolres.932463 $2 doi
035    __
$a (PubMed)23869884
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xr
100    1_
$a Al-Hiti, Hikmet, $d 1970- $7 xx0073834 $u Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic. milan.chovanec@lfmotol.cuni.cz; Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague
245    10
$a L-arginine in combination with sildenafil potentiates the attenuation of hypoxic pulmonary hypertension in rats / $c H. Al-Hiti, M. Chovanec, V. Melenovský, O. Vajnerová, A. Baňasová, J. Kautzner, J. Herget
520    9_
$a Chronic hypoxia induces an increased production of nitric oxide (NO) in pulmonary prealveolar arterioles. Bioavailability of the NO in the pulmonary vessels correlates with concentration of L-arginine as well as activity of phosphodiesterase-5 enzyme (PDE-5). We tested a hypothesis whether a combination of L-arginine and PDE-5 inhibitor sildenafil has an additive effect in reduction of the hypoxic pulmonary hypertension (HPH) in rats. Animals were exposed to chronic normobaric hypoxia for 3 weeks. In the AH group, rats were administered L-arginine during chronic hypoxic exposure. In the SH group, rats were administered sildenafil during chronic hypoxic exposure. In the SAH group, rats were treated by the combination of L-arginine as well as sildenafil during exposure to chronic hypoxia. Mean PAP, structural remodeling of peripheral pulmonary arterioles (%DL) and RV/LV+S ratio was significantly decreased in the SAH group compared to hypoxic controls even decreased compared to the AH and the SH groups in first two measured parameters. Plasmatic concentration of cGMP and NOx were significantly lower in the SAH group compared to hypoxic controls. We demonstrate that NO synthase substrate L-arginine and phosphodiesterase-5 inhibitor sildenafil administered in combination are more potent in attenuation of the HPH compared to a treatment by substances given alone.
650    _2
$a zvířata $7 D000818
650    _2
$a hypoxie $x komplikace $x farmakoterapie $x patofyziologie $7 D000860
650    _2
$a arginin $x aplikace a dávkování $7 D001120
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a synergismus léků $7 D004357
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a plicní hypertenze $x farmakoterapie $x etiologie $x patofyziologie $7 D006976
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a piperaziny $x aplikace a dávkování $7 D010879
650    _2
$a výměna plynů v plicích $x účinky léků $7 D011659
650    _2
$a puriny $x aplikace a dávkování $7 D011687
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Wistar $7 D017208
650    _2
$a sulfony $x aplikace a dávkování $7 D013450
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vazodilatancia $x aplikace a dávkování $7 D014665
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Chovanec, Milan $7 xx0104171 $u Department of Cardiology, Na Homolce Hospital, Prague; Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic
700    1_
$a Melenovský, Vojtěch $7 xx0160847 $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague
700    1_
$a Vajnerová, Olga $7 xx0036859 $u Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic
700    1_
$a Baňasová, Alena, $d 1973- $7 xx0074189 $u Department of Pathophysiology, Second Medical School, Charles University, Prague, Czech Republic
700    1_
$a Kautzner, Josef, $d 1957- $7 xx0037112 $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague
700    1_
$a Herget, Jan, $d 1945-2019 $7 nlk19990073223 $u Department of Physiology, Second Medical School, Charles University, Prague, Czech Republic
773    0_
$w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 62, č. 6 (2013), s. 589-595
910    __
$a ABA008 $b A 4120 $c 266 $y 4 $z 0
990    __
$a 20140825 $b ABA008
991    __
$a 20190920125241 $b ABA008
999    __
$a ok $b bmc $g 1037342 $s 867847
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 62 $c 6 $d 589-595 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
GRA    __
$a NT13358 $p MZ0
LZP    __
$b NLK118 $a Pubmed-20140825

Najít záznam

Citační ukazatele

Možnosti archivace